Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer

Show other versions (1)

What's new? Regulatory T cells (Treg) appear to contribute to poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC), suggesting that Treg cells are key therapeutic targets.

Saved in:

Bibliographic Details
Main Authors:	Shevchenko, Ivan (Author) , Karakhanova, Svetlana (Author) , Soltek, Sabine (Author) , Link, Julia (Author) , Bayry, Jagadeesh (Author) , Werner, Jens (Author) , Umansky, Viktor (Author) , Bazhin, Alexandr V. (Author)
Format:	Article (Journal)
Language:	English
Published:	2013
In:	International journal of cancer Year: 2013, Volume: 133, Issue: 1, Pages: 98-107
ISSN:	1097-0215
DOI:	10.1002/ijc.27990
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ijc.27990 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/10.1002/ijc.27990
Author Notes:	Ivan Shevchenko, Svetlana Karakhanova, Sabine Soltek, Julia Link, Jagadeesh Bayry, Jens Werner, Viktor Umansky and Alexandr V. Bazhin

Description
Summary:	What's new? Regulatory T cells (Treg) appear to contribute to poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC), suggesting that Treg cells are key therapeutic targets.
Item Description:	First published: 12 December 2012 Gesehen am 26.01.2022
Physical Description:	Online Resource
ISSN:	1097-0215
DOI:	10.1002/ijc.27990